China grants patent for PolTREG"s Treg cell therapy for multiple sclerosis

PolTREG has received a patent from China's National Intellectual Property Administration for its PTG-007 Treg cell therapy, which is administered intrathecally to treat multiple sclerosis (MS). This method allows for effective delivery of the therapy across the blood-brain barrier. The company is preparing to initiate two Phase 2 clinical studies in Q4 2024, targeting relapsing-remitting MS and primary progressive MS, with a total of 105 patients involved in the trials. The Phase 1 clinical trial demonstrated promising results, showing that patients receiving intrathecal administration had no increase in existing brain lesions and almost no new lesions. This outcome was significantly better than those treated intravenously. The upcoming studies will further explore the efficacy of PTG-007 in a larger patient population, building on the encouraging data from earlier trials. PolTREG is also advancing its research in Treg therapies for various autoimmune diseases, including type 1 diabetes, where long-term remission has been observed in some patients treated with PTG-007. The company is set to launch a Phase 2 study for presymptomatic type 1 diabetes patients and plans to begin a first-in-human trial of engineered CAR-Treg therapies for MS and amyotrophic lateral sclerosis next year. With a robust GMP-certified manufacturing facility, PolTREG is well-positioned to produce its Treg therapeutics and expand its capabilities for next-generation therapies. The company aims to ship its cellular therapy products across Europe within 24 hours, ensuring timely access to its innovative treatments.